CREO – Creo Medical Group Plc

Creo Medical (LSE:CREO) opened its interim results on 28 July 2026 with the sort of headline number that tends to concentrate investor minds: first-half revenue up 45% to £3.2m. Yet the more telling part of the update sat beneath the top line. The Welsh medtech group paired that growth with a 15% reduction in underlying operating costs and a narrowing of its operating loss, framing a half in which commercial momentum and a leaner cost base were finally pulling in the same direction.

For a company that has spent years funding the long, expensive journey from clever engineering to routine clinical adoption, the combination matters more than either figure in isolation. Management reaffirmed guidance for full-year revenue growth of 50% to 60%, and pointed to an outsourced manufacturing model and fresh financing as the structural changes intended to shorten the road to profitability.

What Creo does

Creo Medical (LSE:CREO) designs advanced energy devices for minimally invasive surgery, concentrating on flexible endoscopy used to detect and treat pre-cancerous and cancerous tissue in the gastrointestinal tract. Its technology aims to let clinicians resect and ablate lesions during an endoscopy rather than sending patients to more invasive open or laparoscopic surgery.

At the centre sits the CROMA platform, powered by the company's proprietary Kamaptive technology. CROMA delivers two energy modalities through a flexible endoscope: advanced bipolar radiofrequency for precise cutting and high-frequency microwave energy for controlled coagulation. Around it Creo has built a family of single-use instruments, including Speedboat for dissection and resection, the SpydrBlade Flex scissor-type dissection tool, and the MicroBlate range of microwave ablation devices. The commercial model is the familiar razor-and-blade approach: place the capital platform, then generate recurring revenue from disposables as procedure volumes build.

The half-year in detail

The reported numbers describe a business scaling revenue while shrinking its cost footprint. Revenue of £3.2m compared with roughly £2.2m in the same period a year earlier, the 45% advance driven by stronger order intake and wider international adoption of its endoscopic devices, with management singling out progress across Latin America.

Underlying operating costs fell to about £7.8m from £9.1m, a 15% reduction that the company attributed largely to restructuring and the decision to outsource manufacturing. The operating loss from continuing operations narrowed to £4.9m from £6.9m, an improvement of more than 25%. On our reading, that widening gap between revenue growth and cost reduction is the clearest evidence yet of operational leverage beginning to appear in the model, even if the group remains some distance from breakeven.

Balance sheet and financing

Cash discipline is the counterweight to that progress. The group closed the half with £7.4m of cash at 30 June 2026, down from £12.4m at the end of December 2025, reflecting continued investment and the cash cost of restructuring.

During the period Creo shored up its balance sheet, raising £5.5m through an equity placing and securing a £2.0m convertible loan note from the Development Bank of Wales. It also flagged the proposed sale of its 49% stake in Creo Medical SL, expected to complete in the third quarter, as a further source of non-dilutive funding. Taken together, these steps buy time, though the pace of the cash outflow means funding remains a live consideration rather than a settled one.

Comparison with earlier periods

Against its own recent history, the direction of travel has clearly shifted. Creo spent much of the past few years as a research-led business absorbing heavy losses while it broadened regulatory clearances and built a clinical evidence base. The current guidance for 50% to 60% full-year growth, and the visible decline in operating costs, mark a transition from that investment-heavy phase toward one where commercial traction is meant to do more of the work.

Clinical adoption metrics reinforce the point. The company reported its first UK private hospital deployment of Speedboat, novel BEAM procedures using SpydrBlade Flex, more than 100 clinical cases for MicroBlate Flex and 50 cases for MicroBlate Fine, evidence that usage is accumulating across its portfolio rather than resting on a single product.

Strategy and growth drivers

Strategically, the plan rests on three pillars: growing recurring disposable revenue as installed platforms are used more intensively, expanding geographically into markets such as Latin America, and lowering the fixed cost of the business through outsourced manufacturing announced in April 2026. Management framed the leaner operating model as the mechanism that allows revenue growth to convert more efficiently into reduced losses.

The recurring-revenue dynamic is the key variable to watch. If the clinical case numbers translate into repeat disposable ordering at scale, the economics improve materially; the razor-and-blade model only rewards Creo once the blades are being reordered in volume.

Industry and competitive context

Creo operates in a well-funded corner of medtech where much larger players in surgical energy and endoscopy compete for the same procedure. Its differentiation lies in combining multiple energy modalities in slim, flexible, single-use instruments aimed at the endoscopic treatment of early-stage cancer, an area where health systems have clear incentives to avoid more invasive and costly surgery. The competitive challenge is less about the underlying science than about persuading clinicians to adopt new workflows and building the reimbursement and training infrastructure that drives routine use.

Risks and uncertainties

The risks are those common to commercialising medtech firms, but they are not trivial here. The group remains loss-making and cash-consumptive, and the fall in cash during the half underlines that further funding or the timely completion of the Creo Medical SL disposal may be needed to sustain the strategy. Guidance of 50% to 60% growth is explicitly weighted to the second half, which raises execution risk should order conversion slip.

Outsourcing manufacturing lowers fixed costs but introduces dependence on third parties for a regulated, quality-critical product. Adoption of novel surgical techniques can also be slow and uneven across geographies, and currency movements add noise to reported international revenue.

Milestones to monitor

Near-term, investors will look for completion of the Creo Medical SL stake sale in the third quarter and for the second-half revenue weighting to materialise in line with guidance. Continued growth in disposable reorders, further clinical case milestones across the MicroBlate and Speedboat ranges, and evidence that the outsourced manufacturing model is delivering the promised cost benefits will all serve as checkpoints ahead of the full-year figures.

A measured conclusion

The interim results present a business moving in the right direction on the metrics that matter most for a scaling medtech: faster revenue growth, lower costs and a narrower loss. CEO Craig Gulliford described a strong first half in which the actions taken had strengthened the group's foundations.

On our reading, the achievement is real but incomplete. Creo has demonstrated it can grow while spending less, yet it has not yet demonstrated that it can do so while generating cash. Whether the second-half-weighted guidance is delivered, and whether recurring disposable revenue compounds, will determine how convincingly the path to scale converts into a path to profitability.